Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
Immunovant, Inc. (IMVT)
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. “We are delighted to welcome Dr. Butchko and Ms. Withington to the Board”, stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. “These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company’s growth.” Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added “I am especially enthusiastic about working with Dr. Butchko and Ms. Withington since they bring considerable strengths in research and development as well as representing the patient perspective as we pursue our mission of delivering new drugs to patients with cancer.”Julia G. Butchko, Ph.D. brings 25 years of industry experience and most re
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024PR Web
- Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024GlobeNewswire
- Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingGlobeNewswire
IMVT
Earnings
- 8/6/24 - Miss
IMVT
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 3
- 11/12/24 - Form SC
- IMVT's page on the SEC website